OncoSec Medical Inc
Expert analysts at HC Wainright
has Buy rating on OncoSec Medical Inc (OTC:ONCS). The firm has started
coverage in an analyst report made public on Tuesday morning. HC
Wainright's target would suggest upside of 246.74% from the company's
last stock close.
The new coverage is welcomed by
equity traders, as OTC:ONCS is currently trading 3.59% higher at $7.21 as
of 07:56 New York time. OncoSec Medical Inc shares have decreased -34.45%
over the last 200 days, while the Standard & Poor's 500 index has
added 6.27% in the same time.
Out of 3 analysts covering
OncoSec Medical Inc, 3 rate it a Buy, 0 indicate a Hold while 0 suggest a
Sell. The highest target is $60 and the lowest is $25 according to
Thomson/First Call. The 12-month mean target is $41.67, which means upside
potential of 477.95% over the current price.
OTC:ONCS Price Chart &
The stock price of OncoSec Medical Inc has decreased 34.45% over the last
200 days, and is in strong down trend. In the last 50 and 100 days,
OncoSec Medical Inc is up 9.24% and down 7.56%, respectively. Our stocks
momentum model is shown on the price chart below